## **Product** Data Sheet

## AZ 11645373

Cat. No.:HY-108670CAS No.:227088-94-0Molecular Formula: $C_{24}H_{21}N_3O_5S$ Molecular Weight:463.51

Target: P2X Receptor

Pathway: Membrane Transporter/Ion Channel

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	AZ11645373 is a highly selective and potent antagonist at human but not rat P2X7 receptors $\square$ AZ11645373 inhibits ATP-evoked IL-1 $\beta$ release from lipopolysaccharide-activated THP-1 cells, with an IC <sub>50</sub> value of 90 nM <sup>[1]</sup> .
In Vitro	AZ11645373 produces a concentration-dependent inhibition of BzATP-mediated calcium transients, with complete inhibition observed at concentrations between 100 and 300 nM according to concentration-inhibition curves $^{[1]}$ . AZ11645373 inhibits ATP- or BzATP-evoked YO-PRO1 fluorescence in HEK cells stably expressing hP2X7R, but not in cells expressing rP2X7R, with an K <sub>B</sub> value not significantly different from those obtained in experiments measuring membrane currents or calcium mobilization $^{[1]}$ . AZ11645373 (0.01, 0.1, 1 $\mu$ M; 30 min) has no significant effect on basal levels of IL-1 $\beta$ in culture medium of LPS-treated cells, but produces a concentration-dependent inhibition of ATP-mediated IL-1 $\beta$ release with a calculated K <sub>B</sub> value of 92 nM $^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Stokes L, et al. Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br J Pharmacol. 2006 Dec;149(7):880-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA